Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms

  • Kevin C Yang
  • Steve E Kalloger
  • John J Aird
  • Michael K C Lee
  • Christopher Rushton
  • Karen L Mungall
  • Andrew J Mungall
  • Dongxia Gao
  • Christine Chow
  • Jing Xu
  • Joanna M Karasinska
  • Shane Colborne
  • Steven J M Jones
  • Jörg Schrader
  • Ryan D Morin
  • Jonathan M Loree
  • Marco A Marra
  • Daniel J Renouf
  • Gregg B Morin
  • David F Schaeffer
  • Sharon M Gorski

Abstract

Pancreatic neuroendocrine neoplasms (PNENs) are biologically and clinically heterogeneous. Here, we use a multi-omics approach to uncover the molecular factors underlying this heterogeneity. Transcriptomic analysis of 84 PNEN specimens, drawn from two cohorts, is substantiated with proteomic profiling and identifies four subgroups: Proliferative, PDX1-high, Alpha cell-like and Stromal/Mesenchymal. The Proliferative subgroup, consisting of both well- and poorly differentiated specimens, is associated with inferior overall survival probability. The PDX1-high and Alpha cell-like subgroups partially resemble previously described subtypes, and we further uncover distinctive metabolism-related features in the Alpha cell-like subgroup. The Stromal/Mesenchymal subgroup exhibits molecular characteristics of YAP1/WWTR1(TAZ) activation suggestive of Hippo signaling pathway involvement in PNENs. Whole-exome sequencing reveals subgroup-enriched mutational differences, supported by activity inference analysis, and identifies hypermorphic proto-oncogene variants in 14.3% of sequenced PNENs. Our study reveals differences in cellular signaling axes that provide potential directions for PNEN patient stratification and treatment strategies.

Bibliographical data

Original languageEnglish
Article number109817
ISSN2211-1247
DOIs
Publication statusPublished - 12.10.2021

Comment Deanary

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

PubMed 34644566